Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Immunol., 22 January 2026

Sec. Cancer Immunity and Immunotherapy

Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1789441

Correction: IL-6/STAT3 signaling in prostate cancer: CAF-driven immune evasion and therapeutic opportunities

This article is a correction to:

  1. IL-6/STAT3 signaling in prostate cancer: CAF-driven immune evasion and therapeutic opportunities

    1. Read original article
Frontiers Production Office* Frontiers Production Office*

    A Correction on
    IL-6/STAT3 signaling in prostate cancer: CAF-driven immune evasion and therapeutic opportunities

    By Zhou T, Li Y, Liu Z, Zeng Z, Li T, Chen L, Zhao H, Wu X, Shen Y, Fan H, Zhu X, Zhou Y, Zou L and Zhao D (2026) Front. Immunol. 16:1736606. doi: 10.3389/fimmu.2025.1736606

    There was a mistake in Figure 1 as published. In the PDF of the article, the revised version of the Figure was not included. However, it is correct on the webpage. The corrected Figure 1 appears below.

    Figure 1
    Diagram illustrating the role of IL-6/CAF axis in prostate cancer. IL-6 interacts with various cells and pathways, driving immune evasion and therapy resistance. Key components include JAK, STAT, and CAF subtypes, such as iCAF and myCAF. The diagram also indicates the tumor microenvironment involving MDSC and CD8+ T cells, and therapeutic strategies such as IL-6 blockade and IL-6R blockade with agents like Tocilizumab. The effects on neuroendocrine differentiation, endocrine/chemotherapy resistance, and pathways for CAF reprogramming and YAP1 inhibition are highlighted.

    Figure 1. Mechanistic overview of IL-6/STAT3 signaling driving tumor progression and immune evasion in prostate cancer.

    The original version of this article has been updated.

    Publisher’s note

    All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

    Keywords: cancer-associated fibroblasts, interleukin-6, prostate cancer, therapeutic resistance, tumor microenvironment

    Citation: Frontiers Production Office (2026) Correction: IL-6/STAT3 signaling in prostate cancer: CAF-driven immune evasion and therapeutic opportunities. Front. Immunol. 17:1789441. doi: 10.3389/fimmu.2026.1789441

    Received: 16 January 2026; Accepted: 16 January 2026;
    Published: 22 January 2026.

    Approved by:

    Frontiers Editorial Office, Frontiers Media SA, Switzerland

    Copyright © 2026 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    *Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.